XL-protein Licenses Technology to MSD

XL-protein Germany, a privately owned biopharmaceutical company, has licensed its proprietary PASylation technology to MSD Animal Health for development of biopharmaceuticals for animal health.

The agreement follows a research collaboration between the German firm and the European arm of US drugmaker Merck & Co begun in 2012. Under the terms, MSD Animal Health will acquire worldwide exclusive rights for certain biopharmaceutical drug candidates.

To support the commercialization effort, XL protein said it will further optimize the drug candidates against undisclosed MSD targets, using its PASylation platform for plasma half-life extension. The technology has previously been used for human health medications.

MSD will be responsible for clinical development and commercialization of biopharmaceuticals generated under the collaboration.

According to XL-protein, the fully biological PASylation technology can be applied to approved biopharmaceuticals to yield second-generation drugs or to innovative therapeutic proteins or peptides, thus allowing less frequent and lower dosing combined with better patient tolerability.

The German company pursues the preclinical and the clinical development of PASylated biologics in commercially attractive disease areas. It also has several collaborations with other companies in the pharma and biotech industries and offers licenses.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.